Drug intelligence / Profile preview

bexirestrant

Development stage: Discontinued
Lead developer: SPARC
Modality: Small Molecules
Administration: Oral

Overview

Bexirestrant (SCO-120) is an orally bioavailable small molecule that functions as a selective estrogen receptor degrader (SERD). It is being developed by Sun Pharma Advanced Research Company for the treatment of advanced or metastatic breast cancer. Bexirestrant binds to and promotes degradation of the estrogen receptor alpha (ERα), thereby inhibiting estrogen signaling pathways that drive tumor growth in ER-positive breast cancers. The drug has reached phase I clinical trials but development was terminated in some regions due to commercial reasons[1][3][5].

Other names: bexirestrantSCO-120SCO120SCO 120

Targets

ESR1 (ERα)

Beyond the preview

Go deeper on bexirestrant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bexirestrant.

Explore the full profile